GlassScriptPhysician profile
Kweku G Sam
NPI 1093789406
$5,988.42
in general payments reported to CMS, 2019-2025
44 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $746 · 2021: $719 · 2022: $528 · 2023: $1,106 · 2024: $745 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $826.75 | 2019-2025 | |
| Sanofi Pasteur INC. | $567.38 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $485.18 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $371.28 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $292.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $279.68 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Genzyme Corporation | $271.78 | 2022-2023 | |
| Kaleo, INC. | $264.51 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $248.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $243.50 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $182.90 | 2024-2025 | |
| Corium, LLC | $175.38 | 2023-2024 | Azstarys |
| Tris Pharma INC | $161.18 | 2019-2023 | Dyanavel Xr |
| Neurelis, INC. | $155.80 | 2021-2024 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kweku Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.